Correlation and survival analysis of SIRT1 expression level and clinicopathological features of breast cancer patients

doi:10.3877/cma.j.issn.1674-0793.2016.01.004

Abstract

Abstract:

Objective

To detect the expression of silent information regulator 1 (SIRT1) in breast cancer and adjacent paracancerous tissues, and to analyze the correlation between its expression level and other clinical features of breast cancer and its significance in prognosis.

Methods

The expression of SIRT1 was detected by immunohistochemistry in 120 breast cancer tissues and 53 adjacent paracancerous tissues. The difference between the two groups and the relationship between SIRT1 expression and other clinical features were tested by chi-square test. Survival analysis was calculated by Kaplan-Meier method, and the survival rate was compared by Log-rank test.

Results

The expression of SIRT1 in breast cancer group was significantly higher than adjacent paracancerous tissues group (53.3% vs 34.0%, χ²=5.533, P=0.02). SIRT1 expression level showed positive correlation with tumor size and expresion of Ki-67 (χ²=6.790, 21.316, P=0.009, 0.000), but no statistical correlation with lymph node metastasis, clinical stage, histological grade, ER, PR and Her-2 expression. Statistical analysis showed that compared with low SIRT1 expression, patients with high SIRT1 expression level had significantly poorer prognosis (χ²=9.320, P<0.05).

Conclusions

The expression of SIRT1 is obviously increased in breast cancer patients than that in adjacent paracancerous tissues, and its expression is correlated with tumor size and expression of Ki-67. These results may implicate that SIRT1 will improve the development of breast cancer and the high-er expression of SIRT1 indicates the activated proliferation and poor survival rate.

Key words: Breast neoplasms, Silent information regulaltor 1, Immuneohistochemistry

Ruilei Liu, Jianning Chen, Jiani Wang, Mi Tang, Yanling Zhang. Correlation and survival analysis of SIRT1 expression level and clinicopathological features of breast cancer patients[J]. Chinese Archives of General Surgery(Electronic Edition), 2016, 10(01): 31-35.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2016.01.004

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2016/V10/I01/31

Figures/Tables 3

References 18

2	Liu T,Liu PY,Marshall GM. The critical role of the class Ⅲ his-tone deacetylase SIRT1 in cancer[J]. Cancer Res, 2009, 69(5): 1702-1705.
3	Song NY,Surh YJ. Janus-faced role of SIRT1 in tumorigenesis[J]. Ann N Y Acad Sci, 2012, 1271: 10-19.
4	Deng CX. SIRT1, is it a tumor promoter or tumor suppressor?[J]. Int J Biol Sci, 2009, 5(2): 147-152.
5	张嘉庆,王殊,谢菲.不断提高我国乳腺癌综合治疗水平[J/CD].中华普外科手术学杂志:电子版, 2011, 5(4): 367-372.
6	Guarente L. Sir2 links chromatin silencing, metabolism, and aging[J]. Genes Dev, 2000, 14(9): 1021-1026.
7	Vaziri H,Dessain SK,Ng EE, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase[J]. Cell, 2001, 107(2): 149-159.
8	Kim EJ,Kho JH,Kang MR, et al. Active regulator of SIRT1 coop-erates with SIRT1 and facilitates suppression of p53 activity[J]. Mol Cell, 2007, 28(2): 277-290.
9	Sung JY,Kim R,Kim JE, et al. Balance between SIRT1 and DBC1 expression is lost in breast cancer[J]. Cancer Sci, 2010, 101(7): 1738-1744.
10	Zschoernig B,Mahlknecht U. SIRTUIN 1: regulating the regulator[J]. Biochem Biophys Res Commun, 2008, 376(2): 251-255.
11	Motta MC,Divecha N,Lemieux M, et al. Mammalian SIRT1 re-presses forkhead transcription factors[J]. Cell, 2004, 116(4): 551-563.
12	Dai JM,Wang ZY,Sun DC, et al. SIRT1 interacts with p73 and suppresses p73-dependent transcriptional activity[J]. J Cell Physi-ol, 2007, 210(1): 161-166.
13	Wong S,Weber JD. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1[J]. Biochem J, 2007, 407(3): 451-460.
14	Li K,Casta A,Wang R, et al. Regulation of WRN protein cellular localization and enzymatic activities by SIRT1-mediat-ed deacetylation[J]. J Biol Chem, 2008, 283(12): 7590-7598.
15	Doyle SL,Donohoe CL,Lysaght J, et al.Visceral obesity, metabol-ic syndrome, insulin resistance and cancer[J]. Proc Nutr Soc, 2012, 71(1): 181-189.
16	Eades G,Yao Y,Yang M, et al. miR-200a regulates SIRT1 ex-pression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells[J]. J Biol Chem, 2011, 286(29): 25992-26002.
1	Jemal A,Bray F,Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
17	Nalls D,Tang SN,Rodova M, et al. Targeting epigenetic regula-tion of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells[J]. PLoS One, 2011, 6(8): e24099.
18	Huffman DM,Grizzle WE,Bamman MM, et al. SIRT1 is signifi-cantly elevated in mouse and human prostate cancer[J]. Cancer Res, 2007, 67(14): 6612-6618.

项目		例数	SIRT1蛋白		χ²值	P值
项目		例数	高表达	低表达	χ²值	P值
年龄（岁）		?	?	?	?	?
?	≤ 45	84	45(53.6)	39(46.4)	?	?
?	>45	36	19(52.8)	17(47.2)	6.006	0.936
肿瘤大小(cm)		?	?	?	?	?
?	≤2	26	8(30.8)	18(69.2)	?	?
?	>2	94	56(59.6)	38(40.4)	6.790	0.009^a
淋巴结转移		?	?	?	?	?
?	-	45	21(46.7)	24(53.3)	?	?
?	+	75	43(57.3)	32(42.7)	1.286	0.257
TNM分期		?	?	?	?	?
?	Ⅰ-Ⅱ	84	41(48.8)	43(51.2)	?	?
?	Ⅲ-Ⅳ	36	23(63.9)	13(36.1)	2.302	0.129
组织学分级		?	?	?	?	?
?	Ⅰ	12	6(50.0)	6(50.0)	?	?
?	Ⅱ	89	48(53.9)	41(46.1)	?	?
?	Ⅲ	19	10(52.6)	9(47.4)	6.070	0.966
ER		?	?	?	?	?
?	阴性	43	23(53.5)	20(46.5)	?	?
?	阳性	77	41(53.2)	36(46.8)	0.001	0.980
PR		?	?	?	?	?
?	阴性	49	30(61.2)	19(38.8)	?	?
?	阳性	71	34(47.9)	37(52.1)	2.072	0.150
Her-2		?	?	?	?	?
?	阴性	87	51(58.6)	36(41.4)	?	?
?	阳性	33	13(39.4)	20(60.6)	3.554	0.059
Ki-67		?	?	?	?	?
?	低表达	63	21(33.3)	42(66.7)	?	?
?	高表达	57	43(75.4)	14(24.6)	21.316	0.000^a

项目		例数	SIRT1蛋白		χ²值	P值
项目		例数	高表达	低表达	χ²值	P值
年龄（岁）		?	?	?	?	?
?	≤ 45	84	45(53.6)	39(46.4)	?	?
?	>45	36	19(52.8)	17(47.2)	6.006	0.936
肿瘤大小(cm)		?	?	?	?	?
?	≤2	26	8(30.8)	18(69.2)	?	?
?	>2	94	56(59.6)	38(40.4)	6.790	0.009^a
淋巴结转移		?	?	?	?	?
?	-	45	21(46.7)	24(53.3)	?	?
?	+	75	43(57.3)	32(42.7)	1.286	0.257
TNM分期		?	?	?	?	?
?	Ⅰ-Ⅱ	84	41(48.8)	43(51.2)	?	?
?	Ⅲ-Ⅳ	36	23(63.9)	13(36.1)	2.302	0.129
组织学分级		?	?	?	?	?
?	Ⅰ	12	6(50.0)	6(50.0)	?	?
?	Ⅱ	89	48(53.9)	41(46.1)	?	?
?	Ⅲ	19	10(52.6)	9(47.4)	6.070	0.966
ER		?	?	?	?	?
?	阴性	43	23(53.5)	20(46.5)	?	?
?	阳性	77	41(53.2)	36(46.8)	0.001	0.980
PR		?	?	?	?	?
?	阴性	49	30(61.2)	19(38.8)	?	?
?	阳性	71	34(47.9)	37(52.1)	2.072	0.150
Her-2		?	?	?	?	?
?	阴性	87	51(58.6)	36(41.4)	?	?
?	阳性	33	13(39.4)	20(60.6)	3.554	0.059
Ki-67		?	?	?	?	?
?	低表达	63	21(33.3)	42(66.7)	?	?
?	高表达	57	43(75.4)	14(24.6)	21.316	0.000^a

[1]	Yang Li, Jinyu Cai, Xiaozhi Dang, Wanying Chang, Yan Ju, Yi Gao, Hongping Song. Application value of a deep learning-based model for generating strain elastography images using breast grayscale ultrasound images [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(06): 563-570.
[2]	Li Lin, Ying Yang, Yi Zhang. Management of axillary lymph nodes in breast cancer in the era of precision medicine [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(04): 193-198.
[3]	Lulan Pu, Jingjia Li, Yu Chen, Yuqing Zhou, Xinxin Rong, Lingmi Hou, Fangfang Zhou. NF2/YAP signaling pathway induces ferroptosis in triple negative breast cancer cells with high expression of CD24 by FSP1 [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(04): 206-211.
[4]	Zhenghong Liu, Chunluan Yuan. Expression of long non-coding RNA BC200 in serum exosomes of breast cancer patients and its clinical significance [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(04): 212-216.
[5]	Xiaoqing Yu, Xin Gao, Wenpei Luo, Lu Yang. Breast cancer risk prediction model for patients with BI-RADS 4 nodules [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(04): 217-223.
[6]	Huan Yang, Liang Ma, Jun Shen, Lili Dong, Wenwen Sun. Correlation of supportive care needs with symptom clusters and coping strategies in breast cancer patients undergoing neoadjuvant chemotherapy [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(04): 224-230.
[7]	Yandong Liu, Hengyu Li. Staging and de-escalating treatment for locoregional area of breast cancer after neoadjuvant chemotherapy [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(03): 146-151.
[8]	Mengni Wu, Zhihua Xu, Yan Chen. Role of DTNBP1 in triple negative breast cancer and its prognostic value [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(03): 158-168.
[9]	Feng Guan, Bin Luo, Xiaokang Ke, Jingping Yuan. Clinicopathological characteristics of invasive lobular carcinoma of the breast with metastases to rare sites [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(03): 169-174.
[10]	Xue Li, Mengmeng Han, Xueyuan Feng, Ning Ma. Progress and challenges of human epidermal growth factor receptor 2-low expressing breast cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(04): 308-312.
[11]	Zhizhao Zhang, Rui Wang, Pingping Gao, Chengfang Wang, Cheng Wang, Xiaowei Qi. Relationship between DNMT3B and prognosis of breast cancer and its biological mechanism [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 624-629.
[12]	Lingyan Wang, Chunhui Gao, Xueyuan Feng, Xinmiao Cui, Huan Liu, Wenming Zhao, Jinku Zhang. Application of circulating tumor cells in neoadjuvant and postoperative adjuvant therapy for breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 630-633.
[13]	Linjuan Zhao, Jie Lv, Wensheng Wang, Demao Ma, Tao Hou. Study on the effect of ultrasound guided resection of stellate and cylindrical lactation preserving areas with staining marks [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 634-637.
[14]	Hong Liu, Pin Wang, Bin Wang, Jiechao Ren, Wenjie Zhang, Jian Wu, Ying Liu. Transaxillary endoscopic assisted subcutaneous glandectomy preserving nipple and areola + Stage Ⅰbreast reconstruction with anterior breast prosthesis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(04): 419-422.
[15]	Leping Kang, Lin Zhang, Zhou Wan, Yong Gou. Analysis of curative effect and complications of endoscopic subcutaneous glandectomy and axillary lymph node dissection combined with prosthesis implantation in the treatment of breast cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(04): 427-429.

Please choose a citation manager

Content to export